Apyx Medical Posts $14M in Third-Quarter Sales
APYX sits 19% above its 52-week low of $2.25.
Summary
Apyx Medical reported third-quarter sales of $14.0 million, up 9% from a year earlier and up from $13.9 million in Q2 2026, which itself was a 22% year-over-year increase. The sequential gain is modest but keeps the top line on the growth path management reaffirmed with its full-year revenue guidance in August. For a company with a market value near $109 million, $14 million in quarterly revenue is the core number traders price off. The release gives no profit, margin, or cash detail, so the read on the bottom line and the company's declining cash reserves is still open. Watch for the full 10-Q and any guidance update, which will show whether the growth is holding and how much cash was used in the quarter.
At the time of this announcement, APYX was trading at $2.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $109.1M. The 52-week trading range was $2.25 to $5.08. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.